v3 Template
K

Kinvard Bio Inc.

Biotechnology / Pharmaceuticals ~440 employees
Founded
--
Employees (Est.)
~440
22 leaders known
Total Funding
$2.7M
Funding Rounds
1
Last Funding
2025-07-29

About Kinvard Bio Inc.

Kinvard Bio, a spin-out from Harvard University's Myers Lab, is dedicated to pioneering the development of a new class of ribosome-targeting antibiotics called oxepanoprolinamides (OPPs). The company focuses on addressing critical unmet patient needs and commercial potential by creating versatile treatment options for acute and chronic bacterial infections, with a strong emphasis on combating antimicrobial resistance (AMR).

Products & Services

Oxepanoprolinamides (OPPs):A novel class of ribosome-targeting antibiotics with broad-spectrum activity against Gram-positive and Gram-negative bacteria, designed for both IV and oral administration, effective against multidrug-resistant pathogens, and targeting acute and chronic infections.
Cresomycin:An antibiotic preorganized for ribosomal binding, designed to overcome antimicrobial resistance.
KV-001:In Lead Optimization stage, targeting Hospital-Acquired and Ventilator-Acquired Bacterial Pneumonia (HABP/VABP) and complicated Urinary Tract Infections (cUTI), focusing on resistant Gram-negative bacteria.
KV-002:Advancing through Lead Optimization towards Investigational New Drug stage for Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), targeting major resistant pathogens.
KV-003:In discovery stage, progressing OPPs for additional clinical indications like nontuberculosis mycobacterial lung disease (NTM-LD) with high unmet patient need.

Specialties

Ribosome-targeting antibiotics Antimicrobial resistance (AMR) Oxepanoprolinamides (OPPs) Broad-spectrum antibacterial activity Synthetic chemistry platform IV and oral drug delivery Chronic and acute bacterial infections

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Non-dilutive funding
T: -
FT: Non-dilutive funding 		A: 2700000
MR: -
FA: US$2.7 million
FAN: 2700000 		D: 2025-07-29
FD: 2025-07-29 		1 investors
Non-dilutive funding Latest
2025-07-29
$2.7M
1 investor (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

S

Steve Gelone

Chairman

LinkedIn (Pro only)
N

Nathan Finger

Director, Operations

LinkedIn (Pro only)
O

Obadiah Plante

SVP, Head of Research

LinkedIn (Pro only)
K

Kelvin Wu

Co-founder & Director, Platform Development

L

Lloyd J. Payne

Chief Executive Officer

A

Andrew G. Myers

Amory Houghton Professor of Chemistry

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

Kinvard Bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Pharmaceuticals
Company Size
~440 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro